Moclobemide (Manerix--Roche), the first of a new class of antidepressant drugs, was launched in the UK last year. It is a reversible inhibitor of monoamine oxidase A, which the manufacturer claims is a "first line treatment for major depression". Is this claim justified?
吗氯贝胺(商品名:Manerix,罗氏公司生产)是新型抗抑郁药物中的首个产品,于去年在英国上市。它是一种单胺氧化酶A可逆抑制剂,制造商宣称它是“重度抑郁症的一线治疗药物”。这一宣称合理吗?